Open AccessP895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D‐VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS
Author(s) -
Fu W.,
Li W.,
Hu J.,
An G.,
Wang Y.,
Fu C.,
Chen L.,
Jin J.,
Cen X.,
Ge Z.,
Cai Z.,
Niu T.,
Qi M.,
Gai X.,
Li Q.,
Liu W.,
Liu W.,
Yang X.,
Chen X.,
Lu J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846452.85760.1b
Subject(s) - medicine , daratumumab , bortezomib , dexamethasone , interim analysis , lenalidomide , multiple myeloma , clinical endpoint , gastroenterology , surgery , randomized controlled trial